Morepen Laboratories Limited announces the launch of Empamore, a game-changing treatment for Type 2 Diabetes Mellitus (T2DM), Heart Failure with Reduced Ejection Fraction (HFrEF), and Chronic Kidney Disease (CKD). With India being the diabetes capital of the world and over 101 million people suffering from the disease, Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health.

Speaking on the launch, Ashutosh Sharma, V.P. - Sales & Marketing, Morepen Laboratories, said: “At Morepen, we are dedicated to democratizing healthcare by making world-class treatments accessible to all. With Empamore, we are providing a trusted, high-quality diabetes treatment at nearly 90% lower cost than existing brands, helping millions manage their condition effectively without financial strain. This aligns with our commitment to empower people to take charge of their health.”

Morepen manufactures Empagliflozin (API) in its USFDA-approved facilities and already has a European DMF. The launch of Empamore reflects Morepen’s 40 years of pharmaceutical excellence, providing a cost-effective alternative to leading brands while ensuring affordability without compromising quality.

Empagliflozin is a globally recognized SGLT2 inhibitor, widely used for diabetes management. With pre-diabetes cases in India rising to nearly 136 million and the diabetes market expected to grow at a CAGR of 10.9%, Morepen’s launch of Empamore comes at a crucial time to provide an affordable and effective solution.